Financial Performance
5Y price score: 519
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 1,526%
US$ Per
Share
By default your notes are visible only to you.
712.0
52-week range
1292.6
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
1.8 %
Dividend Yield TTM
0.5 %
Market cap $
$ 1,161,628
Price / Earnings TTM
41.4
Price / Book TTM
32.5
PEG TTM
1.6
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
78.3 %
376.2 %
1,526 %
Free cash flow per share growth
508.7 %
113.8 %
725.1 %
Earnings per share growth
26.2 %
254.7 %
952.8 %
Founded: 1,876
Employees: 43,000
Business Summary:
Latest Earnings Call Takeaways
2026 Q2 (Aug 5, 2026)
1) Strong Financial Performance - Revenue growth of 48% YoY, driven by Key Products, particularly Oncology, Immunology, and Neuroscience, which collectively grew 121%. - Non-GAAP earnings per share reached $8.38, up from $6.31 in Q2 2025. - Gross margin improved to 86.3%, reflecting a favorable product mix and production costs. - U.S. revenue increased by 33%, with notable contributions from Zepbound and Mounjaro.
2) Pipeline Advancements and Regulatory Milestones - Significant progress in the pipeline, including FDA approval of Ebglyss for atopic dermatitis and EU approval for Jaypirca in CLL. - Foundayo launched in the U.S. for obesity, with early uptake in the UAE showing promise. Regulatory reviews ongoing in over 40 countries. - Positive Phase 3 results for retatrutide in obesity and diabetes, with plans for a BLA submission in Q1 2027.
3) Strategic Acquisitions and Business Development - Acquired companies like Curevo and AtaiBeckley to expand into infectious diseases and mental health treatments. - Focus on building a robust internal pipeline through strategic business development, enhancing Lilly's position in emerging therapeutic areas.
4) Market Dynamics and Competitive Landscape - The Medicare GLP-1 Bridge program launched, increasing access to obesity medicines for 20 million Americans. - Foundayo's U.S. launch is gaining momentum, with a noted increase in prescribers from 8,000 to 36,000. - Competitive pressures from other oral treatments in the obesity market, particularly in the UAE, but Lilly maintains a strong market position.
5) Guidance and Future Outlook - Full-year revenue guidance raised to between $85 billion and $87 billion, reflecting strong performance. - Non-GAAP performance margin expected between 49% and 50.5%. - Anticipated deceleration in revenue growth in the latter half of 2026 due to prior period adjustments and seasonality effects.
Bottom line: Eli Lilly's robust financial performance, strategic pipeline advancements, and proactive market positioning suggest a strong outlook for continued growth, making it an attractive prospect for shareholders despite potential competitive challenges.
Annual Reports, Presentations And IR Contacts
Go to the websiteEli Lilly And Co — Financial Overview, Stock Price, Market Cap
Eli Lilly And Co is a company. Founded in 1876. As of August 26, 2026, the company's market capitalization is $1161628106090 with a current stock price of $1233.49.